Back
  • There are no suggestions because the search field is empty.

Press releases

Explore our latest news, updates and announcements
September 5, 2024

AP-HP has selected Aiforia as a partner for AI-assisted pathology image analysis

Aiforia Technologies Plc, Press Release, September 5, 2024 at 09:00 a.m. EEST Assistance Publique–Hôpitaux de Paris (AP-HP) has selected Aiforia Technologies Plc as a partner for AI-assisted pathology image analysis in clinical diagnostics. The collaboration involves the use of the Aiforia Clinical AI solutions for the analysis of tissue samples from prostate cancer patients.
August 1, 2024

Aiforia selected to provide AI solutions for breast and prostate cancer diagnostics for Fimlab Laboratories

Aiforia Technologies Plc, Press release August 1, 2024 at 09:00 am EEST Fimlab Laboratories Ltd has selected Aiforia Technologies Plc as the provider for breast and prostate cancer diagnostics solutions. Fimlab is Finland’s largest healthcare laboratory company, owned by the wellbeing services counties of Pirkanmaa, Central Finland, Kanta-Häme, Ostrobothnia, and Päijät-Häme.
July 23, 2024

Aiforia selected to provide AI-assisted diagnostics in the Castile and León region in Spain

Aiforia Technologies Plc, Press Release, July 23, 2024 at 01:00 p.m. EEST The regional health management of Castile and León in Spain has selected Aiforia Technologies Plc as a partner for AI-assisted diagnostics. The contract is part of a tender with an initiative to improve the diagnostic workflow of the region's pathology laboratories, including, for example, an image management system ...
May 15, 2024

Aiforia wins a framework agreement to provide AI solutions for Fimlab Laboratories in Finland

Aiforia Technologies Plc Press release 15 May 2024 at 03:30 pm EEST Aiforia has been selected to conclude a framework agreement to provide AI solutions to Fimlab Laboratories in Finland to support Diagnostics in pathology.
May 3, 2024

Aiforia delivers AI-powered digital pathology solutions through Google Cloud Marketplace

Aiforia Technologies Plc, Press Release, May 3, 2024 at 11:00 a.m. EEST Aiforia Technologies Plc announces its clinical software solutions for AI-powered pathology image analysis are now available on Google Cloud Marketplace. By establishing a new sales and marketing channel on the Google Marketplace, Aiforia enables pathology laboratories using Google Cloud to simplify their procurement process ...
April 24, 2024

Aiforia signs a contract with a veterinary health company in the US

Aiforia Technologies Plc, Press Release, April 24, 2024 at 09:00 a.m. EEST A global leader in veterinary health and innovative diagnostic devices, based in the United States, has selected Aiforia Technologies Plc as its partner for AI-assisted image analysis in animal samples. The total value of the contract is approximately USD 200 thousand.
March 6, 2024

Aiforia releases Aiforia® Studies, a pioneering GLP-compliant AI-assisted image analysis workflow for non-clinical histology studies

Aiforia Technologies Plc, Press Release, March 6, 2024 at 09:00 a.m. EET
January 2, 2024

Aiforia signs a licensing agreement with the Mayo Clinic for an AI model that improves prediction of colorectal cancer recurrence

Aiforia Technologies Plc, Press release, January 2, 2024 at 10.00 a.m. EET Aiforia has entered into an exclusive licensing agreement with the Mayo Clinic in the United States to globally commercialize an AI model that improves prediction of colorectal cancer recurrence. The AI model was developed in collaboration with the Mayo Clinic. The AI model identifies important histological features of ...
December 27, 2023

Aiforia signs a deal with an Italian hospital in Catania

Aiforia Technologies Plc, Press Release, December 27, 2023 at 01:00 p.m. EET
December 21, 2023

Looking back on 2023: A year of important milestones

Dear customers, shareholders, and our team, As we stand at the threshold of a new year, I wanted to take a moment to review the events of 2023 and express my gratitude for your continued support and hard work that the team has done. It has been a year of important milestones for Aiforia as the first deployments of our clinical AI-solutions were kicked-off in key markets.
October 20, 2023

Aiforia initiates path to secure its first regulatory approval in the United States – application to the FDA anticipated in 2024

Aiforia Technologies Plc, Press Release, October 20, 2023 at 10:00 a.m. EEST
September 18, 2023

Aiforia complies with applicable HIPAA regulations, enabling it to provide solutions to a broader range of customers in the US

Aiforia Technologies Plc, Press Release, 18 September 2023 at 09:00 a.m. EEST
July 5, 2023

Aiforia and Orion collaborate to develop AI solutions for image analytics in drug research

Aiforia Technologies Plc, Press Release, 05 July 2023 at 12:00 a.m. EEST
June 29, 2023

Aiforia signs a major deal with an Italian Regional Health Authority

Aiforia Technologies Plc Inside information 29 June 2023 at 10:30 a.m. EEST
April 27, 2023

Aiforia has received a funding decision from Business Finland to accelerate the development of AI-assisted software solutions for clinical pathology and drug development

Aiforia Technologies Plc, Company release, 27 April 2023 at 12:00 a.m. EEST. Aiforia has received a funding decision from Business Finland to accelerate the development of AI-assisted software solutions for clinical pathology and drug development.
April 4, 2023

First NHS Trust has signed a contract to adopt Aiforia PD-L1 AI model for lung cancer in clinical diagnostics

Aiforia Technologies Plc, Press Release, 04 April 2023 at 12:00 a.m. EEST. The first NHS Trust of the PathLAKE Plus consortium has signed an individual contract to adopt Aiforia PD-L1 AI model for lung cancer in clinical diagnostics. The duration of the contract is three years, with a possible three-year extension.
February 10, 2023

Aiforia receives a contract award to provide AI solutions for 25 NHS hospitals of the PathLAKE Plus consortium in the UK

Aiforia has received a contract award to provide artificial intelligence solutions for 25 NHS Trusts pathology departments in the UK to support the diagnosis of patients. The Contract Award enables the Trusts to purchase directly from Aiforia and to sign individual contracts without worksome tender processes. The technology of the awarded vendor has already been qualified for clinical use, and ...
October 31, 2022

Introducing Aiforia Education

Aiforia is excited to present the newly rebranded Aiforia Education, formerly known as Aiforia Hub for Education. What is Aiforia Education? Aiforia Education is a cloud-based software for e-learning that allows teachers to unbind themselves and their students from microscopes, classrooms, and printed materials. The platform enables educators to upload sample images from any microscope scanner ...
June 14, 2022

Aurora mScope partners with Aiforia to Bring Integrated AI and Image Management Systems to Pathologists

With this integration, pathology departments can utilize Aiforia’s clinical grade, CE-IVD marked AI models or ones built using Aiforia Create, and automatically import the results into Aurora mScope Clinical, with its rich image management, case management, workflow, and reporting feature set.
June 9, 2022

Aiforia makes key advancement towards end-to-end clinical pathology workflow solution with the release of its CE-IVD marked Aiforia® Clinical Suite Viewer

Aiforia Technologies Plc is thrilled to announce it received CE-IVD marking for the Aiforia® Clinical Suite Viewer, a cloud-based platform enabling a holistic approach to cancer diagnostics and prognostics through the viewing of whole slide digital images of human histopathological samples and deep learning AI produced results along with their seamless reporting. The Aiforia viewer provides ...
May 27, 2022

Aiforia releases another CE-IVD marked clinical AI Model — expanding its diagnostic pathology offering to prostate cancer

This latest regulatory certification brings Aiforia’s portfolio of AI-powered diagnostic tools to a total of 5 CE-IVD marked clinical AI models for breast, lung, and now prostate cancer — the most commonly occurring cancer in men. According to the World Cancer Research Fund, more than 1.4 million new cases of prostate cancer were diagnosed in 2020. Both pathologists and patients deserve reliable ...
May 25, 2022

Aiforia adds fourth CE-IVD marked clinical AI Model to its rapidly expanding portfolio of novel tools for cancer diagnostics

Aiforia is providing a uniquely comprehensive approach to breast cancer diagnostics as the majority of cases express ER and/or PR. Therefore, the two are considered to be the most significant biomarkers involved in the evaluation of breast cancer.
May 5, 2022

Aiforia Technologies Plc appoints Vice President of Sales for Europe

Aiforia has appointed Tamas Regenyi as Vice President of Sales, Europe. The position will be essential to driving Aiforia’s business strategy in the region; focusing on accelerating growth in Aiforia’s established preclinical market in acquiring large customers in the pharmaceutical industry as well as advancing Aiforia’s position in the clinical diagnostics market for pathology.
April 20, 2022

Aiforia expands its portfolio of CE-IVD marked clinical pathology solutions with new AI model for breast cancer diagnostics

Aiforia Technologies Plc, Press Release, 20 April, 2022 at 09.30 a.m. EEST. Aiforia Technologies Plc announces the CE-IVD marking of the Aiforia® Clinical AI Model for Breast Cancer; ER. Adding to its repertoire of CE-IVD marked clinical AI models for cancer diagnostics, the new AI model automates the calculation of estrogen receptors (ER) — a group of proteins present in the majority of breast ...
February 15, 2022

Aiforia signs agreement with South Korean biotech company to augment its novel drug discovery platform with AI

The two companies announced an agreement to add Aiforia’s artificial intelligence technology to Genuv’s ATRIVIEW® proprietary drug discovery platform, used to screen both existing drugs and new substances for neuroprotective and neuroregenerative effects. ATRIVIEW® was used to discover Genuv’s leading drug candidate, SNR1611, which has shown the ability to restore CNS function in preclinical ...
January 12, 2022

Aiforia launches a collaboration with Mayo Clinic to transform pathology practice with AI-powered solutions

Aiforia, a technology company providing deep learning AI software for image analysis in pathology, and Mayo Clinic announced today that they are collaborating to establish an AI-powered pathology research support architecture at the Mayo Clinic. Leveraging each other’s expertise in digital pathology and deep learning, the two aim to enable faster results and scalable studies in translational ...
November 16, 2021

Aiforia achieves CE-IVD mark for clinical PD-L1 AI model in lung cancer diagnostics

Worldwide the most common cause of cancer mortality in 2020 was lung cancer, with an estimated 1.80 million deaths occurring¹. Fortunately immunotherapies are increasing in prominence and efficacy². A popular target for these novel therapeutics is PD-L1, a vital biomarker indicating cancer progression³. The calculation of PD-L1 presence in tumors is routinely used in clinical pathology as a ...
September 23, 2021

Aiforia Earns ISO 27001 Security Certification

Aiforia has received ISO 27001 certification, the premier global standard for Information Security Management Systems. With this certification, Aiforia highlights its mission to maintain the highest standards for information security in its AI-assisted digital pathology products.
September 16, 2021

Aiforia Announces Closing of €17.5M Series B Funding Round

HELSINKI, Sept 16, 2021 -- Aiforia, a software company providing AI-based solutions for clinical diagnostics and preclinical analysis to enable pathologists to translate medical images into diagnoses and discoveries with more efficiency and precision, announced today the completion of a €17.5M Series B funding round. The funding round is led by Epredia's UK entity, a subsidiary of PHC Holdings ...
August 19, 2021

Aiforia and CompuMed collaborate to enhance organ transplant pathology with AI

CompuMed and its team of highly experienced physicians provide specialized diagnostic interpretations to their clients who need answers in high urgency situations. Organ Procurement Organizations (OPOs) which provide organs and tissue for transplant centers need critical information relating to for example pathology, cardiology, or radiology to improve donor management, decrease donor evaluation ...
June 21, 2021

Epredia and Aiforia announce partnership for global distribution of AI-powered pathology software

Portsmouth, NH, USA, June 21, 2021 – Epredia, a global leader in precision cancer diagnostics, and Aiforia, a medical software company providing Artificial Intelligence (AI) based solutions for image analysis in pathology, have announced today that they have entered into a commercial distribution agreement for Aiforia’s comprehensive portfolio of workflow enhancing solutions which enable ...
June 10, 2021

Aiforia announces CE-IVD mark for AI-supported breast cancer diagnostics

First-of-its kind diagnostic tool Aiforia today announced the CE-IVD Mark for the Aiforia® Clinical AI Model for Breast Cancer; Ki67, a widely used key biomarker in breast cancer diagnostics across pathology labs around the world. The AI Model is able to calculate Ki67 positive and negative cells in invasive areas of human breast tissue in whole slide images (WSI) as well as in specific areas — ...
June 3, 2021

Aiforia Raises €12.6M in Series B Funding to Enhance Precision Diagnostics and Preclinical Analysis in Pathology

Helsinki – June 3, 2021 - Aiforia, a software company providing AI-based solutions for clinical and preclinical image analysis in pathology, announced today the closing of the first €12.6M tranche of their Series B round. The funding round has the potential to reach €25.2M if investors exercise the optional second tranche. The funding round is led by Epredia's UK entity, a subsidiary of PHC ...
April 22, 2021

Aiforia and X-ZELL partner to scale up novel AI-powered method for early cancer detection

Singapore, Helsinki -- Aiforia, a leading software company providing artificial intelligence (AI) solutions for medical image analysis, and X-ZELL, a clinical stage med-tech company aiming to make early, affordable cancer detection accessible to everyone, have entered into a strategic partnership to integrate X-ZELL’s novel rare cell detection technology with Aiforia’s deep learning AI software.
April 8, 2021

New Finnish consortium aims to enhance diagnostics and combat pandemics

The COVID-19 pandemic has highlighted the importance of efficient diagnostic methods. Beyond battling pandemics, there are also significant diagnostic needs in everyday healthcare but healthcare systems around the world are struggling with rapidly increasing costs. The Future of Diagnostics (FUDIS) co-innovation consortium was created to address these challenges — to develop reliable, rapid, ...
March 15, 2021

Aiforia appoints Swedbank as lead advisor to explore financing options

Aiforia Technologies Oy ("Aiforia" or "the Company") has appointed Swedbank AB (publ) as their lead financial advisor to explore different financing options, including possibilities for an Initial Public Offering (IPO) by listing the Company's shares on Nasdaq Helsinki First North.
October 21, 2020

Aiforia Announces Formation of Scientific Advisory Board

Aiforia, a leading provider of deep learning artificial intelligence (AI) solutions for image analysis across a variety of medical domains, announces its newly formed Scientific Advisory Board. The four advisors represent world-class expertise in clinical diagnostics, personalized medicine, digital and computational pathology.
September 1, 2020

€2.1M EU funding takes Aiforia to the clinic

Supporting pathologists in cancer diagnostics The €2.1M funding was awarded to Aiforia Technologies as part of the European Union’s Horizon 2020 research and innovation programme and enables the health tech company to launch itself into the diagnostics space. Aiforia’s vision is that AI will become a mandatory tool for doctors, soon a visual diagnosis will not be made without the assistance of AI.